As of 2025-01-16, the EV/EBITDA ratio of SAGE Therapeutics Inc (SAGE) is -0.62. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SAGE's latest enterprise value is 229.00 mil USD. SAGE's TTM EBITDA according to its financial statements is -371.26 mil USD. Dividing these 2 quantities gives us the above SAGE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.9x - 15.0x | 13.7x |
| Forward P/E multiples | 14.8x - 19.8x | 15.5x |
| Fair Price | (119.51) - (120.50) | (117.54) |
| Upside | -1746.2% - -1759.7% | -1719.1% |
| Date | EV/EBITDA |
| 2025-01-14 | -0.65 |
| 2025-01-13 | -0.65 |
| 2025-01-10 | -0.41 |
| 2025-01-08 | -0.44 |
| 2025-01-07 | -0.46 |
| 2025-01-06 | -0.49 |
| 2025-01-03 | -0.48 |
| 2025-01-02 | -0.44 |
| 2024-12-31 | -0.39 |
| 2024-12-30 | -0.39 |
| 2024-12-27 | -0.41 |
| 2024-12-26 | -0.43 |
| 2024-12-24 | -0.40 |
| 2024-12-23 | -0.39 |
| 2024-12-20 | -0.42 |
| 2024-12-19 | -0.34 |
| 2024-12-18 | -0.34 |
| 2024-12-17 | -0.37 |
| 2024-12-16 | -0.38 |
| 2024-12-13 | -0.39 |
| 2024-12-12 | -0.42 |
| 2024-12-11 | -0.45 |
| 2024-12-10 | -0.41 |
| 2024-12-09 | -0.41 |
| 2024-12-06 | -0.42 |
| 2024-12-05 | -0.41 |
| 2024-12-04 | -0.42 |
| 2024-12-03 | -0.41 |
| 2024-12-02 | -0.44 |
| 2024-11-29 | -0.40 |
| 2024-11-27 | -0.41 |
| 2024-11-26 | -0.43 |
| 2024-11-25 | -0.38 |
| 2024-11-22 | -0.36 |
| 2024-11-21 | -0.32 |
| 2024-11-20 | -0.33 |
| 2024-11-19 | -0.33 |
| 2024-11-18 | -0.31 |
| 2024-11-15 | -0.35 |
| 2024-11-14 | -0.39 |
| 2024-11-13 | -0.43 |
| 2024-11-12 | -0.43 |
| 2024-11-11 | -0.50 |
| 2024-11-08 | -0.50 |
| 2024-11-07 | -0.50 |
| 2024-11-06 | -0.46 |
| 2024-11-05 | -0.46 |
| 2024-11-04 | -0.44 |
| 2024-11-01 | -0.47 |
| 2024-10-31 | -0.47 |